---
figid: PMC9400130__etm-24-03-11500-g02
pmcid: PMC9400130
image_filename: etm-24-03-11500-g02.jpg
figure_link: /pmc/articles/PMC9400130/figure/f3-ETM-24-3-11500/
number: Figure 3
figure_title: ''
caption: Evaluation of the accuracy and sensitivity of LTBP2 as a biomarker for BCR
  of PCa. (A and C) ROC curve and its AUC value in (A) GEO-merged datasets and (C)
  validation dataset (GSE70769). (B and D) The relative expression levels of LTBP2
  in (B) TCGA-PRAD dataset and (D) a validation dataset (GSE70769). LTBP2, latent
  transforming growth factor Î²-binding protein 2; BCR, biochemical recurrence; PCa,
  prostate cancer; ROC, receiver operating characteristic; AUC, area under the curve;
  GEO, Gene Expression Omnibus; TCGA, The Cancer Genome ATLAS; PRAD, prostate adenocarcinoma;
  Pri-, primary.
article_title: LTBP2 inhibits prostate cancer progression and metastasis via the PI3K/AKT
  signaling pathway.
citation: Xiaowen Zhang, et al. Exp Ther Med. 2022 Sep;24(3):563.
year: '2022'

doi: 10.3892/etm.2022.11500
journal_title: Experimental and Therapeutic Medicine
journal_nlm_ta: Exp Ther Med
publisher_name: D.A. Spandidos

keywords:
- prostate cancer
- The Cancer Genome Atlas
- Gene Expression Omnibus
- tumor microenvironment
- immunotherapy
- LTBP2

---
